Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18584889 | 0.87 | MPO (0.39) | MPOMAP4K3PLK1FFAR1FFAR4 | |
| SCHEMBL18585012 | 0.86 | MPO (0.42) | MPOSLC6A4 | |
| SCHEMBL18585182 | 0.85 | MPO (0.44) | MPOPLK1SGMS2 | |
| SCHEMBL18585151 | 0.85 | MPO (0.62) | MPOMAOBSLC6A4 | |
| SCHEMBL18621531 | 0.82 | MPO (0.62) | MPOMAP4K3MAOBSLC6A4 | |
| SCHEMBL18621127 | 0.81 | TLR8 (0.46) | MPOIDO1MAP4K3EGFRSGMS2 | |
| SCHEMBL18585159 | 0.81 | MPO (0.44) | MPO | |
| SCHEMBL18585277 | 0.81 | MPO (0.51) | MPO | |
| SCHEMBL18584987 | 0.81 | MPO (0.52) | MPO | |
| SCHEMBL18584970 | 0.81 | MPO (0.43) | MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MPO 2/4885IDO1 208/4885MAP4K3 2127/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885IDO1 208/4885MAP4K3 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.